Harry is an early-career researcher in bioengineering. He's an advocate of programmable medicine, a new paradigm in therapy. In this paradigm, nucleic acids such as mRNA or DNA are coded and therapeutically used to program our body to fight against invading viruses or cancer. Harry developed the first mRNA therapeutic program in Australia at MIPS in 2018, and used mRNA to develop a candidate vaccine against COVID-19. The vaccine platform can be used to address other emerging viral epidemics. Harry focuses on inventions and innovation, where the impact is achieved through collaboration with industry, developing and commercialising pharmaceutical technologies, and an unwavering focus on solving real-world problems through therapeutic and biotechnological innovations.